Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

Clinical trial NCT07704658 · RECRUITING

Trial details

NCT number: NCT07704658
Sponsor: Rigel Pharmaceuticals
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)Thyroid Cancer Solid Tumor Malignancies Advanced Malignancies

Start date: 2026-03-04
Primary completion: 2027-07-30
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.